Background
The link between osteoporosis-related fragility fractures and mortality has been established by studies conducted across the globe over the last 3 decades, especially for hip fractures [
1‐
10]. These studies show that in different countries with different types of healthcare systems, a fragility fracture was associated with a greater risk of mortality within the first year following the fracture and remained increased for several years after. Similar results have been reported in Canada [
4,
7‐
10], whereby a fragility fracture occurring at any osteoporotic site increased mortality risk by 1.4–1.5-fold in adults aged 50 years and older [
4]. When examining specific fragility fracture sites, a 2–4-fold mortality risk increase was observed after hip, vertebral or humerus (in men) fractures in Canadians aged 50 and older [
4,
7,
8], while several other fracture sites were found to be associated with a 1.4–2-fold mortality risk increase (rib, humerus, forearm, or pelvic fracture in women; wrist fracture in men) [
4,
8].
In spite of this mortality burden, a large gap currently exists for the primary prevention of fracture, and studies show that an estimated 80–90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting [
11‐
13]. In contrast, approximately 90% of patients with cardiovascular disease are provided appropriate secondary preventive care [
14]. System-level and country-level healthcare initiatives have been implemented worldwide to focus on addressing the secondary fracture prevention gap [
15,
16], with several reports showing these initiatives being effective in not only reducing subsequent fragility fracture rates but also associated mortality [
17‐
20]. Considering these data and the current fracture prevention gap, it is important to further improve knowledge of mortality associated with fragility fractures among medical or non-medical professionals involved in osteoporosis care [
11‐
13,
21‐
23].
Studies examining post-fracture mortality after non-hip fractures over the past decade have typically focused on younger patient populations (aged ≥ 50 years), while studies examining mortality risk in adults aged > 65 have focused primarily on hip fractures [
4,
7‐
10]. As such, there is a gap in understanding the mortality risks post fracture occurring at any or non-hip osteoporotic sites in adults aged > 65. Within this group, due to age-related fracture risk increase, more serious recommendations currently exist for fracture risk assessment or pharmacological intervention for osteoporosis [
24,
25], and therefore the closing of the fracture prevention gap is that much more important.
The primary objective of this study was to utilize health services data from the publicly funded healthcare system in Canada to assess mortality post-fracture in a large, real-world cohort of adults aged > 65 years who experienced an index fragility fracture of any osteoporotic and non-hip site between 2011 and 2015, in comparison to matched non-fracture controls. Secondarily, surgeries and complications, which partly relate to mortality, were analyzed for all fragility fracture sites examined in this study.
Methods
Study design
A population-based retrospective matched-cohort study was conducted using public healthcare databases including health services records for about 13 million people living in Ontario, Canada. Primary databases used to identify and describe cases in this study were the Registered Persons Database (RPDB), Discharge Abstract Database (DAD)/ Same Day Surgery (SDS), National Ambulatory Care Reporting System (NACRS), and Ontario Health Insurance Plan (OHIP) (Supplementary Table
1). Healthcare encounters were recorded in multiple record-level, administrative datasets in the ICES Data Repository, and encrypted patient-specific identifiers (ICES-specific key number [IKN]) were used to link the administrative datasets.
Participants and setting
Included in the fracture cohort were Ontario residents aged 66 years and older (> 65) with an index fracture occurring at an osteoporotic fracture site from January 1, 2011 to March 31, 2015, identified from acute hospital admissions, emergency and ambulatory care using International Classification of Diseases (ICD)-10 diagnostic codes for fracture (Supplementary Table
2) as a main diagnosis or admitting diagnosis (ie, if no definite diagnosis was made, the main symptom, abnormal finding or problem was selected) [
26]. Patients with fractures occurring at the following osteoporotic fracture sites were included in the fracture cohort: hip, vertebral (clinical), wrist (distal radius, or both distal radius and ulna), clavicle/sternum, rib, humerus, tibia/fibula/knee (including medial and lateral malleolus), pelvis, radius/ulna (proximal, midshaft, or distal ulna only), multisite, femur. Patients were excluded if they presented with an index fracture of non-osteoporotic fracture sites (ie, skull, face, hands, and feet) or their index fracture was associated with a trauma code (Supplementary Table
3) to maximize the probability that only fragility fractures were examined [
9]. Patients were also excluded if they experienced a previous fracture during the 5-year lookback period prior to the index fracture date to minimize the likelihood that post index fracture mortality was influenced by a recent fracture occurring prior to an index event.
Patients in the fracture cohort were matched 1:1 to controls (non-fracture cohort) from the Registered Persons Database (RPDB) who did not experience a fracture between January 1, 2011 and March 31, 2015 or during the 5-year lookback period prior to their index date. Matching was performed based on the following a priori specified variables: month and year of index date (random index date assigned to controls); sex; age groups (66–70, 71–75, 76–80, 81–85, ≥86 years); geography (rural/urban); and comorbidities (respiratory conditions: asthma, chronic obstructive pulmonary disorder [COPD]; inflammatory conditions: rheumatoid arthritis, psoriasis, spondylarthritis; cancer within 5 years; chronic kidney disease; diabetes; vascular events: myocardial infarction, stroke and cerebrovascular events; dementia; and osteoarthritis).
Data were analysed from the index date until March 31, 2017 (Supplementary Fig.
1). Index date was defined as the date of the index fracture in the fracture cohort and the date of when the follow-up was initiated in the non-fracture cohort. Thus, depending on the index date, the opportunity for follow-up ranged between 2 years (2015–2017) and 6 years (2011–2017). Data from 5 years prior to the index date were also collected to describe clinical characteristics in both cohorts.
Study size
The fracture cohort included all Ontario residents who experienced a fragility fracture that were registered in the DAD/SDS and NACRS using the above-specified criteria for osteoporotic fracture sites and non-trauma fractures, and were able to be matched to the non-fracture controls using the above-specified matching criteria (see Participants and setting section). Both sets of criteria were specified a priori to minimize selection bias. The cohort was limited to those aged 66 years and older (> 65) to collect medication data based on public drug coverage for at least 1 year prior to the index fracture. The 2011–2015 index period was selected to allow at least 2 years of follow-up post-index date and was based on data availability in the ICES Data Repository when the data collection started in 2018.
Variables and data sources
Identifying mortality
Deaths occurring due to any cause from the index date until end of the study period were obtained from the RPDB for both fracture and non-fracture cohorts.
Fracture-related orthopedic surgical procedures (initial and revision) were assessed from the date of index fracture until the end of follow-up in the fracture cohort using the DAD/SDS and Canadian Classification of Health Interventions (CCI) codes (Supplementary Table
4), and surgery-related complications were assessed up to 30 days after an index event using the DAD / SDS, NACRS, and OHIP databases based on ICD-9 or 10 codes (Supplementary Table
5). Vertebroplasty and balloon kyphoplasty were not included in the analysis of fracture-related orthopedic surgical procedures, because these procedures are typically not performed as part of the standard initial orthopedic management of vertebral fractures, as their primary aim is to minimize complications associated with severe and/or multiple vertebral fractures (kyphosis). For deaths and surgical procedures, a minimum follow-up of 1 year was required, but longer follow-up was permitted.
Identifying fractures
Index and second fragility fractures occurring during the follow-up period were examined in the fracture cohort using the DAD/SDS for inpatient visits and NACRS for emergency and ambulatory visits. For the second fragility fractures, the same criteria were applied to examine fractures occurring at osteoporotic sites without trauma as for the index fractures (see Participants and setting section). Fracture of the same site that was dated within 91 days of the index fracture was assumed to stem from the same fracture and was not counted as a second fracture [
27]. The anatomical location of multisite index fracture was used to exclude a subsequent single-site fracture occurring in a similar location within 91 days.
Identifying clinical characteristics
The following databases were used to assess clinical characteristics at the time of the index date in the fracture and non-fracture cohort: RPDB for age and sex; Ontario Drug Benefit (ODB) for medications; and DAD/SDS, NACRS, OHIP, Ontario Rheumatoid Arthritis Administrative Database, Ontario Cancer Registry, Ontario Renal Reporting System, Ontario Diabetes Database, Ontario Myocardial Infarction Database, ASTHMA, COPD for comorbidities using the ICD-9 or ICD-10 codes where applicable.
Statistical methods
Cumulative proportions of deaths due to any cause within 1, 2 or 3 years after an index fracture occurring at any site (fracture cohort) or start of follow-up (non-fracture cohort) were calculated separately for women and men and expressed as absolute risks and absolute risk differences (fracture cohort – non-fracture cohort). Crude relative risks were calculated for women and men (fracture cohort/non-fracture cohort). Adjustment for confounders was not deemed necessary in light of these large cohorts being matched on many a priori specified potential confounders. Survival analysis was conducted using Kaplan-Meier estimates with log rank statistics for evaluation of statistical significance for comparisons between the fracture and non-fracture cohorts.
Cumulative proportions of deaths due to any cause within 1, 2 or 3 years after index fracture were further stratified for fracture cohort participants by hip vs non-hip fracture site and by age categories (66–70, 71–75, 76–80, 81–85, 86+ years). For each fracture site, proportions of deaths, fracture-related surgeries or complications within 1 year were calculated.
Discussion
This study of adults aged > 65 confirms that a fragility fracture of any site is associated with increased mortality risk [
4]. Survival declined over 1–6 years post-fracture with the steepest reduction occurring within the first year, when the crude relative risk was 2.47- and 3.22-fold higher in matched fractured vs non-fractured women and men, respectively. Absolute mortality risk within 1-year post-fracture was 12.5% in women with fractures and 19.5% in men with fractures, with a large absolute risk difference when compared to matched non-fracture controls of 7.4% (95% CI 7.1–7.7%) in women and 13.5% (95% CI 12.9–14.0%) in men.
To add context to the 1-year absolute mortality risk of 14.4% post-index fracture at any site observed in our fracture cohort of women and men (50% aged ≥81), a 1-year absolute mortality risk of 9.7% was observed post-index acute myocardial infarction in Canadians admitted to a hospital between 2006 and 2010 (22% aged 65–74, 35% aged ≥75) [
28]. When considering stroke-related mortality, an absolute mortality risk of 19.3% was reported at discharge in Canadians hospitalised due to ischemic stroke between 2003 and 2004 (aged ≥70, 55% aged > 80) [
29]. Furthermore, an absolute mortality risk of 14.9% was observed within 30 days in-hospital in Canadians admitted to hospital with any stroke in 2012 (25% aged 70–79, 38% aged ≥80) [
30]. Considering that significant reductions in mortality risks associated with cardiovascular events have been reported over the past few decades [
30‐
32], this data demonstrating a clear association between fragility fracture and mortality risk further highlights the need for effective measures to improve osteoporosis management and prevention of fragility fractures in older adults [
11‐
13,
17‐
19,
21‐
23].
Only one study published over the last decade examined mortality post-fragility fracture at any osteoporotic site in Canadians [
4,
7‐
10]. This study of the prospective CaMos cohort (
N = 7689; 72% women) which was younger (mean age 66 and IQR 59–73 years) than our cohort observed age-adjusted hazard ratios (95% CI) of 1.43 (1.24–1.64) and 1.42 (1.12–1.79) in fractured women and men, respectively [
4]. The higher relative mortality risk increase post-fracture observed in our cohort compared to the CaMos cohort was likely partly driven by the higher number of hip fractures in our older cohort, since hip fracture numbers increase in older individuals. The mortality rate observed in our cohort was approximately 2-fold higher in hip fracture compared to non-hip fracture cases in both women and men over the three years post-fracture. However, non-hip fractures also contributed to increased mortality rate observed for all fractures combined, considering the 1.4–1.9- and 1.7–2.4-times greater mortality rate observed, respectively, in women and men with non-hip fracture vs no fracture. Data on non-hip fracture mortality rates in similar cohorts is lacking; however, the 1-year hip fracture mortality rate of 21.5% in women and 32.3% in men observed in our cohort was relatively similar to a 2013 Canadian cohort study of adults aged ≥ 65 which observed a 1-year hip fracture mortality rate of 22% in women and 33% in men [
9]. Although not as common as hip fracture, femur, multisite, pelvis and vertebral fractures were also associated with relatively high 1-year mortality rate in this cohort compared to other fracture sites. Prior studies conducted in similar cohorts have also reported significantly increased mortality after pelvis and vertebral fractures [
4,
7,
8].
The relative difference in mortality rate between fracture and non-fracture cases was observed to decline with increasing age in both women and men, although it remained approximately 2-3x higher even in women and men aged 86+ years. This age-related trend was also observed in prior research and has been attributed to younger adults having much lower absolute mortality rates and as such the excess mortality discrepancy between the younger and older groups may reflect the life expectancy gap in the general population [
33]. Alternatively, younger individuals who experience fragility fracture at younger age may have a poorer health status for their age, compared to older individuals with fragility fractures [
33]. The latter explanation calls for urgency to prevent fragility fractures in younger populations, however, further research is needed to help elucidate this age discrepancy.
Gender trends in our study showed that, although men made up about one-quarter of index fracture cases, they contributed to about one-third of deaths. Although the mortality rate was also higher in men vs women in the non-fracture cohort, this gender difference was slightly larger in the fracture cohort for all fractures combined, hip fractures or non-hip fractures. Compared to women, Canadian men were also previously observed to have significantly higher mortality risk after hip [
8,
9], vertebral [
4,
7,
8], and humerus fractures [
4,
8]. Interestingly, the range in absolute mortality rate based on age was found to be wider in women with approximately 6–7-fold difference between the oldest and youngest age groups compared to men with approximately 4–5-fold difference. Perhaps younger men with fragility fracture may be more vulnerable than older men when compared to women of their respective age groups, or alternatively older women approach closer to older men in terms of their vulnerability. Although we observed a higher relative risk difference in mortality rate between women and men of younger age groups compared to older age groups, this observation was not unique to the fracture cohort. Further, research examining mortality rate post-facture and interactions between sex and age is needed to help confirm and elucidate these observations.
Strengths of this study include having examined large fracture and non-fracture cohorts closely matched on age, sex, geography and comorbidities. A hard match method was used due to the limited number of covariates that were deemed important from a clinical point of view, and 88% of the full unmatched cohort was closely matched with the non-fracture cohort on these covariates. The matched fracture cohort was also similar to the full unmatched fracture cohort, supporting the generalizability of the findings of the matched analysis. Real-world data was captured through all fracture care-related public healthcare services from a province contributing to over one-third of fractures nationally [
34]. Estimates of mortality risks in Canadian adults were reported as up to date, with previous studies relying on 1986–2013 data [
4,
7‐
10]. Finally, Canadians aged > 65 were examined, who based on age alone are recommended for fracture risk assessments due to their age-related fracture risk [
24], but have not been the focus of prior non-hip fracture mortality studies [
4,
7‐
10].
Limitations of this study include the potential for residual confounding which always exists in any observational study, even after yielding a good match in our study based on a number of clinically relevant potential confounders. Another limitation stems from estimating crude mortality risks without adjusting for potential confounders that could not be used during matching, such as a number of and/or time to second fracture, which was previously found to be associated with increased mortality risk [
6]. By excluding patients from the fracture cohort who had another fracture 5 years prior to their index event, but not beyond those 5 years, the fracture cohort was potentially biased towards an older population; this resulted in a mean age roughly 5 years higher than expected for adults aged > 65 [
35]. By excluding patients from the non-fracture cohort who experienced a fracture 5 years prior to their index date, but not beyond those 5 years, the non-fracture cohort might have included a small proportion of fractured patients. There may be an underestimation of the number of fractures in this cohort, particularly non-hip, considering that only the ‘Most Responsible Diagnosis (ie, if no definite diagnosis was made, the main symptom, abnormal finding, or problem was selected)’ [
26] and ‘Pre-Admit Comorbidity’ were used to identify index fractures. Vertebral fractures were likely underestimated considering that two-thirds are typically silent and that ‘Most Responsible Diagnosis’ was used to identify index fractures [
36,
37]. Vertebral fractures could also be more thoroughly identified using the Wright et al. [
27] algorithm which takes into account imaging codes in addition to fracture diagnosis codes. As in prior healthcare database research, the determination of fragility fracture was based on the exclusion of high-trauma ICD codes and not independent adjudication [
9], which may have under/overestimated the number of fragility fractures in this cohort. Cause of death was unavailable and represents an opportunity for further research. Finally, while these results may be generalizable to populations similar to that of Ontario, there may be less generalizability to specific race and ethnic groups [
27].
.
Acknowledgements
This study made use of de-identified data from the ICES Data Repository, managed by the ICES with support from its funders and partners: Canada’s Strategy for Patient-Oriented Research (SPOR), the Ontario SPOR Support Unit, the Canadian Institutes of Health Research and the Government of Ontario. The opinions, results, and conclusions reported are those of the authors. No endorsement by ICES or any of its funders or partners is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. Medical writing assistance was provided by Khalid Siddiqui from Amaris Consulting UK Ltd. and Kyle Willms from Amaris Conseil Inc., and funded by Amgen. The authors would like to thank Arpit Chhabra and Erika Martire for their data summary support on the manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.